Clinical trials: Chorea, Huntington
Biospecimen Donation, Brain Injury
University of Central Florida CereBank
Millions of persons are affected by brain diseases. The CereBank will be used to support research studies aimed at improving the diagnosis and treatment of brain diseases.
- Conditions
- Biospecimen Donation, Brain Injury, Brain Diseases
- Trial name
- NCT06876857
- Where
- United States
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- University of Central Florida
Alzheimer's Disease, Huntington's Disease
A Phase 1, Randomized, Open-Label, Two-Way Crossover Study To Evaluate The Steady-State Effect Of Dimebon (PF 01913539) On The Single-Dose Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects
This study will evaluate the potential drug-drug interaction of Dimebon with the FDA-recommended CYP2C9 substrate warfarin in healthy subjects.
- Trial name
- NCT00827034
- Testing
- Warfarin, Dimebon
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pfizer
Huntington Disease
Mitochondrial Biomarkers in Huntington's Disease
The objective of this study is to discover a panel of mitochondrial metabolomics biomarkers for Huntington's disease.
- Trial name
- NCT04515550
- Testing
- lumbar puncture
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Parkinson Disease, Huntington Disease
Group Drum-Based Music Therapy Intervention for Parkinson's Disease/Huntington's Disease
Participants in this study (18-89 years) with Parkinson's disease or Huntington's disease receive drum classes twice a week for 12 weeks (24 lessons).
- Trial name
- NCT05157074
- Testing
- Group Drumming Music Therapy
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Neurodegenerative Diseases
Exploring the Recovery Function of Sleep in Neurodegeneration
The overall objective of this study is to identify the best approach for assessing the recovery function of sleep in neurodegenerative diseases associated with abnormal protein aggregation with regard to the conception of future…
- Trial name
- RFSN (NCT05402488)
- Testing
- Auditory stimulation
- Where
- Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Huntington Disease
Cooperative Huntington's Observational Research Trial
The purpose of this study is to collect prospective data from individuals who are part of a Huntington Disease (HD) family, in order to relate phenotypes between individuals and families with each other and genetic factors in…
- Trial name
- NCT00313495
- Where
- 52 sites in United States, Australia and 1 more
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- HP Therapeutics Foundation
Huntington's Disease
Escalating Dose Study in Healthy Volunteers With SEN0014196
This is a trial in healthy volunteers to study the safety, tolerability and pharmacokinetics of single and multiple escalating doses of SEN0014196.
- Trial name
- NCT01521832
- Testing
- SEN0014196
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Siena Biotech S.p.A.
Huntington's Disease
Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers
Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 ( 5 mg, 10 mg, 20 mg and 40 mg ) in Healthy Young Male Volunteers
- Trial name
- NCT02208934
- Testing
- PBF-999
- Where
- 2 sites in Spain
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Huntington Disease
CKD-504 in SAD and MAD in Healthy Korean and Caucasian Adult Male and Female Subjects
To assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending oral doses of CKD-504 compared to placebo in healthy Korean and Caucasian adult subjects
- Trial name
- NCT03713892
- Testing
- CKD-504
- Where
- South Korea
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Parkinson Disease, Huntington Disease
Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.
The underlying goal of this study is to assess [123I]MNI-420 SPECT imaging as a tool to detect A2aR density in the brain of PD and HD research participants to be compared with similarly aged healthy subjects.
- Trial name
- MNI-420 (NCT00970229)
- Testing
- [123I]MNI-420
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Caregiver of Huntington's Disease Patient
Caregiver Burden in Huntington's Disease
Huntington's disease (HD) is a rare inherited neurodegenerative disorder, progressing between 15 and 20 years and affecting one person out of 10.000.
- Trial name
- PHRI-HD (NCT02876445)
- Testing
- ZARIT Burden Interview
- Where
- France
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Huntington Disease
Mass Balance Study of [14C] LPM3770164 in Healthy Participants
This is a phase 1, single-center, single-dose, open-label mass-balance study to evaluate radioactive recovery rate, radioactive PK characteristics, metabolite identification, and to observe the safety in healthy male subjects of…
- Trial name
- NCT07516899
- Testing
- [14C] LPM3770164
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Alzheimer's Disease, Huntington's Disease
A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin
To estimate the absorption, safety, and tolerability of a dimebon transdermal solution relative to the dimebon immediate release oral formulation.
- Trial name
- NCT00990613
- Testing
- Dimebon IR, Dimebon Transdermal
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Pfizer
Huntington Disease
Preparing for Prevention of Huntington's Disease (PREVENT-HD)
This is a prospective investigation which aims to address key challenges to the design of clinical trials to prevent the onset of Huntington's disease (HD).
- Trial name
- PREVENT-HD (NCT04818060)
- Testing
- Clinical Assessments, MRI Scan, Lumber Puncture (LP)
- Where
- United States
- Volunteers
- 258 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Huntington Disease, Tardive Dyskinesia
A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects
This is a single-center, randomized, double-blinded, placebo-controlled, dose escalation trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy…
- Trial name
- NCT05238701
- Testing
- LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Huntington Disease
Accelerated Diffusion MRI for Diagnosis of Hungtington Disease
The hypotheses of the project are 1. Diffusion MRI using compressed sensing could have reduced motion sensitivity and improved susceptibility related artifact because of accelerated acquisition. 2.
- Trial name
- NCT01884181
- Where
- Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Wang . Jiun-Jie
Health Volunteers, Huntington Disease
A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease
The purpose of this study is to demonstrate engagement of pridopidine with S1R and D2R (optional) in the living human brain. No formal statistical analysis will be conducted
- Trial name
- NCT03019289
- Testing
- pridopidine (90 mg)
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Prilenia
Huntington Disease
Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease
The purpose of this project is to study brain energy profile evolution at different stages of the Huntington disease.
- Trial name
- PRO-MH2 (NCT01696708)
- Testing
- 31-Phosphorus RMN Spectroscopy
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Huntington's Disease (HD)
Biology-Driven Cognitive Profiling in Huntington's Disease
Huntington's disease (HD) is a genetic, progressive neurodegenerative disorder characterized by early and widespread brain changes that can begin more than a decade before the onset of unequivocal motor signs.
- Trial name
- NCT07503743
- Where
- Spain
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Huntington Disease, HD
iMagemHTT-009- FIH Evaluation of Novel Mutant Huntingtin PET Radioligand [11C]CHDI-00491009
This is a FIH (first-in-human) study to evaluate the clinical utility of the radioligand [11C]CHDI-00491009 as a PET tracer that binds specifically to mutant huntingtin (mHTT) aggregates in Huntington's disease (HD).
- Conditions
- Huntington Disease, HD, PET Tracer, Positron Emission Tomography
- Trial name
- iMagemHTT-009 (NCT06634628)
- Testing
- Radioligand [11C]CHDI-00491009
- Where
- Belgium
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- CHDI Foundation, Inc.